The endocannabinoid system: A drug discovery perspective

Current Opinion in Investigational Drugs

Volumn 6, Issue 7, 2005, Pages 672-679

  Piomelli, Daniele ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

2 arachidonoylglycerol; Anandamide; Anxiety; Cannabinoid receptors; Fatty acid amide hydrolase; Obesity; Pain

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N MORPHOLINO 1H PYRAZOLE 3 CARBOXAMIDE; 3 (2 IODO 5 NITROBENZOYL) 1 (1 METHYL 2 PIPERIDINYLMETHYL)INDOLE; 4 [4 (1,1 DIMETHYLHEPTYL) 2,6 DIMETHOXYPHENYL] 6,6 DIMETHYLBICYCLO[3.1.1]HEPT 2 EN 2 YLMETHANOL; 4 CHLORO N [[3 (4 CHLOROPHENYL) 4 PHENYL 2 PYRAZOLIN 1 YL](METHYLAMINO)METHYLENE]BENZENESULFONAMIDE; AJULEMIC ACID; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; CANNABIS; CARBAMIC ACID DERIVATIVE; CELL SURFACE RECEPTOR; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; ENDOCANNABINOID; ESTER DERIVATIVE; G PROTEIN COUPLED RECEPTOR; GW 405833; IMIDAZOLE DERIVATIVE; KDS 2000; LY 2077855; N (4 HYDROXYPHENYL)ARACHIDONAMIDE; RIMONABANT; SAB 378; TETRAHYDROCANNABINOL; TETRAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANALGESIA; ANALGESIC ACTIVITY; ANXIETY; APPETITE; CLINICAL TRIAL; COGNITIVE DEFECT; DRUG ABSORPTION; DRUG CONTROL; DRUG MECHANISM; DRUG STRUCTURE; FATIGUE; GENE ACTIVATION; GOVERNMENT REGULATION; HUMAN; MOOD; NEUROPATHIC PAIN; NONHUMAN; OBESITY; PAIN; PATHOPHYSIOLOGY; PROTEIN FUNCTION; RECEPTOR BLOCKING; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS; SYNTHESIS; TISSUE DISTRIBUTION; WEIGHT REDUCTION; XEROSTOMIA;

ANIMALS; CLINICAL TRIALS; DRUG DESIGN; ENDOCANNABINOIDS; HUMANS; RECEPTORS, CANNABINOID; SIGNAL TRANSDUCTION;

EID: 21344432777     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI: Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature (1990) 346(6284):561-564.
2. Booth B, Zemmel R: Prospects for productivity. Nat Rev Drug Discov (2004) 3(5):451-456.
3. Freund T, Katona I, Piomelli D: Role of endogenous cannabinoids in synaptic signaling. Physiol Rev (2003) 83(3):1017-1066.
4. Piomelli D: The molecular logic of endocannabinoid signalling. Nat Rev Neurosci (2003) 4(11):873-884.
5. Kunos G, Batkai S, Offertaler L, Mo F, Liu J, Karcher J, Harvey-White J: The quest for a vascular endothelial cannabinold receptor. Chem Phys Lipids (2002) 121(1-2):45-56.
6. Di Marzo V, Bifulco M, De Petrocellis L: The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov (2004) 3(9):771-784.
7. Rinaldi-Carmona M, Barth F, Heaulme M, Shire D, Calandra B, Congy C, Martinez S, Maruani J, Neliat G, Caput D, Ferrara P et al: SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett (1994) 350(2-3):240-244.
8. Hall W, Solowij N: Adverse effects of cannabis. Lancet (1998) 352(9140):1611-1616.
9. 2 function. Neuroscience (1999) 91(2):607-620.
10. Giuffrida A, Parsons LH, Kerr TM, Rodríguez de Fonseca F, Navarro M, Piomelli D: Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosci (1999) 2(4):358-363.
11. Martin RS, Secchi RL, Lemaire M, Bonhaus DW, Hedley LR, Lowe DA: Effects of cannabinoid receptor ligands on psychosis-relevant behavior models in rat. Psychopharmacology (2003) 165(2):128-135.
12. Meltzer H, Arvanitis L, Bauer D, Rein W: Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Am J Psychiatry (2004) 161(6):975-984.
13. Colombo G, Agabio R, Diaz G, Lobina C, Reali R, Gessa GL: Appetite suppression and weight loss after the cannabinoid antagonist SR141716. Life Sci (1998) 63(8):PL113-PL117.
14. 1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset. Behav Pharmacol (1998) 9(2):179-181.
15. Di Marzo V, Golparaju SK, Wang L, Liu J, Batkai S, Jarai Z, Fezza F, Miura GI, Palmiter RD, Sugiura T, Kunos G: Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature (2001) 410(6830):822-825.
16. Drugs in Development. sanofi-aventis has released more positive data for Acomplia: www. diabetes in control.com, USA (2004): November 16. http://www.diabetesincontrol.com/modules.php?name=News&file= article&sid=2238
17. Farrigan C, Pang K: Obesity market overview. Nat Rev Drug Discov (2002) 1(4):257-258.
18. 1 selective cannabinoid antagonist AM281: A potential human SPECT ligand. AAPS Pharmsci (1999) 1(2):E4.
19. 1 cannabinold receptor antagonists. J Med Chem (2004) 47(3):627-643.
20. Schwartz MW, Woods SC, Porte D Jr, Seeley RJ, Baskin DG: Central nervous system control of food intake. Nature (2000) 404(6778):661-671.
21. 1 receptor antagonists as promising new medications for drug dependence. J Pharmacol Exp Ther (2005) 312(3):875-883.
22. Cota D, Marsicano G, Tschop M, Grubler Y, Flachskamm C, Schubert M, Auer D, Yassouridis A, Thone-Reineke C, Ortmann S, Tomassoni F et al: The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest (2003) 112(3):423-431.
23. 1 receptors by vagal afferent neurons is inhibited by cholecystokinin. J Neurosci (2004) 24(11):2708-2715.
24. 1 cannabinoid receptor-dependent modulation of feeding. J Neurosci (2002) 22(21):9612-9617.
25. 1 cannabinoid receptors in haemorrhagic shock. Nature (1997) 390(6659):518-521.
26. Kolata G: Calls for caution as obesity drug stirs up a whirlwind of hopes. New York Times December 5 (2004):1.
27. 1 cannabinoid receptor antagonist SR141716A induces anxiety-like responses in the rat. Neuroreport (1997) 8(2):491-496.
28. 1 cannabinoid receptors in emotional behaviour. Psychopharmacology (2002) 159(4):379-387.
29. 1 cannabinoid receptor antagonist, potentiates the locomotor stimulant effects of amphetamine and apomorphine. Behav Pharmacol (1999) 10(4):429-432.
30. Wagner JA, Varga K, Kunos G: Cardiovascular actions of cannabinoids and their generation during shock. J Mol Med (1998) 76(12):824-836.
31. Batkai S, Pacher P, Osei-Hyiaman D, Radaeva S, Liu J, Harvey-White J, Offertaler L, Mackie K, Rudd MA, Bukoski RD, Kunos G: Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. Circulation (2004) 110(14):1996-2002.
32. Walker JIM, Huang SM: Cannabinoid analgesia. Pharmacol Ther (2002) 95(2):127-135.
33. Ware M, Doyle CR, Woods R, Lynch ME, Clark AJ: Cannabis use for chronic non-cancer pain: Results of a prospective survey. Pain (2003) 102(1-2):211-216.
34. Svendsen K, Jensen TS, Bach FW: Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. Br Med J (2004) 329(7460):253.
35. Attal N, Brasseur L, Guirimand D, Clermond-Gnamien S, Atlami S, Bouhassira D: Are oral cannabinoids safe and effective in refractory neuropathic pain? Eur J Pain (2004) 8(2):173-177.
36. Calignano A, La Rana G, Giuffrida A, Piomelli D: Control of pain initiation by endogenous cannabinoids. Nature (1998) 394(6690):277-281.
37. 1 receptors. Pain (1998) 75(1):111-119.
38. Price TJ, Helesic G, Parghi D, Hargreaves KM, Flores CM: The neuronal distribution of cannabinold receptor type 1 in the trigeminal ganglion of the rat. Neuroscience (2003) 120(1):155-162.
39. Bridges D, Rice AS, Egertova M, Elphick MR, Winter J, Michael GJ: Localisation of cannabinoid receptor 1 in rat dorsal root ganglion using in situ hybridization and immunohistochemistry. Neuroscience (2003) 119(3):803-812.
40. Woolf C: Dissecting out mechanisms responsible for peripheral neuropathic pain: Implications for diagnosis and therapy. Life Sci (2004) 74(21):2605-2610.
41. Ingram R, Jones MG, McMahon SB: Cannabinoid actions in neuropathic pain. Abs Soc Neuroscience (2004) 34:Abs 522.7.
42. 9-tetrahydrocannabinol attenuates capsaicin-induced thermal nociception in rhesus monkeys: A peripheral cannabinoid action. Psychopharmacology (1999) 143(3):322-326.
43. Rukwied R, Watkinson A, McGlone F, Dvorak M: Cannabinoid agonists attenuate capsaicin-induced responses in human skin. Pain (2003) 102(3):283-288.
44. Burstein SH, Karst M, Schneider U, Zurier RB: Ajulemic acid: A novel cannabinoid produces analgesia without a "high". Life Sci (2004) 75(12):1513-1522.
45. Rhee MH, Vogel Z, Barg J, Bayewitch M, Levy R, Hanus L, Breuer A, Mechoulam R: Cannabinol derivatives: Binding to cannabinoid receptors and inhibition of adenylylcyclase. J Med Chem (1997) 40(20):3228-3233.
46. Gottshall S, Harrison J, Pearson M, Turchin P, Chaffer S, Whitehead J, Hachicha M, Walker K, Pomonis JD: Comparison of ajulemic acid and WIN-55,212-2 in models of neuropathic, inflammatory and acute pain. Abs Soc Neuroscience (2004) 34:Abs 173.5.
47. Karst M, Salim K, Burstein S, Conrad I, Hoy L, Schneider U: Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: A randomized controlled trial. J Am Med Assoc (2003) 290(13):1757-1762.
48. Indevus Pharmaceuticals Inc: Product pipeline. Company Web Site (2005) www.indevus.com
49. Novartis AG: Novartis R&D Day 2002: An innovative pipeline keeping the momentum. Company Presentation (2002): October 17.
50. Kadmus Pharmaceuticals Inc: Clinical pipeline. Company Web Site (2004). http://www.kadmuspharma.com/pipeline.asp
51. Munro S, Thomas KL, Abu-Shaar M: Molecular characterization of a peripheral receptor for cannabinoids. Nature (1993) 365(6441):61-65.
52. 2 cannabinold receptors by AM1241 inhibits experimental neuropathic pain: Pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci USA (2003) 100(18):10529-10533.
53. 2 cannabinoid receptor agonists: Pain relief without psychoactive effects? Curr Opin Pharmacol (2003) 3(1):62-67.
54. 2 receptors supresses spinal fos protein expression and pain behavior in a rat model of inflammation. Neuroscience (2003) 119(3):747-757.
55. 2 receptors suppresses hyperalgesia evoked by intradermal capsaicin. J Pharmacol Exp Ther (2004) 308(2):446-453.
56. Valenzano K, Tafesse L, Lee G, Harrison JE, Boulet JM, Gottshall SL, Mark L, Pearson MS, Miller W, Shan S, Rabadi L et al: Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy. Neuropharmacology (2005) 48(5):658-672.
57. 2, a peripheral cannabinoid receptor. Proc Natl Acad Sci USA (1999) 96(25):14228-14233.
58. Pharmos Corp: Pharmos Corporation; fact sheet January 2002. Company Brochure (2002): January.
59. Beltramo M, Stella N, Calignano A, Lin SY, Makriyannis A, Piomelli D: Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science (1997) 277(5329):1094-1097.
60. Fegley D, Kathuria S, Mercier R, Li C, Goutopoulos A, Makriyannis A, Piomelli D: Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172. Proc Natl Acad Sci USA (2004) 101(23):8756-8761.
61. Porter A, Li J, Love PL, Shannon HE, Li DL, Phebus LA, Gleason SD, Witkin JM, Simmons RM, Iyengar S, Nomikos GG: A novel, potent, selective, non-endocannabinoid related inhibitor of anandamide inactivation demonstrates robust analgesic effects in an in vivo pain model. Abs Soc Neuroscience (2004) 34:Abs 273.11.
62. Cravatt BF, Lichtman AH: Fatty acid amide hydrolase: An emerging therapeutic target in the endocannabinoid system. Curr Opin Chem Biol (2003) 7(4):469-475.
63. Dinh TP, Carpenter D, Leslie FM, Freund TF, Katona I, Sensi SL, Kathuria S, Piomelli D: Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci USA (2002) 99(16):10819-10824.
64. Dinh T, Kathuria S, Piomelli D: RNA interference suggests a primary role for monoacylglycerol lipase in the degradation of the endocannabinoid 2-arachidonoylglycerol. Mol Pharmacol (2004) 66(5):1260-1264.
65. Gulyas AI, Cravatt BF, Bracey MH, Dinh TP, Piomelli D, Boscia F, Freund TF: Segregation of two endocannabinoid-hydrolyzing enzymes into pre- and postsynaptic compartments in the rat hippocampus, cerebellum and amygdala. Eur J Neurosci (2004) 20(2):441-458.
66. Cravatt BF, Demarest K, Patricelli MP, Bracey MH, Gjang DK, Martin BR, Lichtman AH: Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci USA (2001) 98(16):9371-9376.
67. Walker JM, Huang SM, Strangman NM, Tsou K, Sanudo-Pena MC: Pain modulation by release of the endogenous cannabinoid anandamide. Proc Natl Acad Sci USA (1999) 96(21):12198-12203.
68. Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG, Hermann H, Tang J, Hofmann C, Zieglgansberger W, Di Marzo V, Lutz B: The endogenous cannabinoid system controls extinction of aversive memories. Nature (2002) 418(6897):530-534.
69. Boger DL, Sato H, Lerner AE, Hedrick MP, Fecik RA, Miyauchi H, Wilkie GD, Austin BJ, Patricelli MP, Cravatt BF: Exceptionally potent inhibitors of fatty acid amide hydrolase: The enzyme responsible for degradation of endogenous oleamide and anandamide. Proc Natl Acad Sci USA (2000) 97(10):5044-5049.
70. Lichtman A, Leung D, Shelton CC, Saghatelian A, Hardouin C, Boger DL, Cravatt BF: Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: Evidence for an unprecedented combination of potency and selectivity. J Pharmacol Exp Ther (2004) 311(2):441-448.
71. Kathuria S, Gaetani S, Fegley D, Valino F, Duranti A, Tontini A, Mor M, Tarzia G, La Rana G, Calignano A, Giustino A et al: Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med (2003) 9(1):76-81.
72. Tarzia G, Duranti A, Tontini A, Piersanti G, Mor M, Rivara S, Plazzi PV, Park C, Kathuria S, Piomelli D: Design, synthesis and structure-activity relationships of alkylcarbamic acid aryl esters, a new class of fatty acid amide hydrolase inhibitors. J Med Chem (2003) 46(12):2352-2360.
73. Mor M, Rivara S, Lodola A, Plazzi PV, Tarzia G, Duranti A, Tonfini A, Piersanti G, Kathuria S, Piomelli D: Cyclohexylcarbamic acid 3′- or 4′-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: Synthesis, quantitative structure-activity relationships and molecular modeling studies. J Med Chem (2004) 47(9):4998-5008.
74. Freund T: Interneuron diversity series: Rhythm and mood in perisomatic inhibition. Trends Neurosci (2003) 26(a):489-495.